Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05936359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05936359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 25, 2023
Completion date
February 29, 2028
Enrollment
160 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasms